These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2288 related articles for article (PubMed ID: 23559152)
1. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152 [TBL] [Abstract][Full Text] [Related]
2. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648 [TBL] [Abstract][Full Text] [Related]
3. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572 [TBL] [Abstract][Full Text] [Related]
4. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141 [TBL] [Abstract][Full Text] [Related]
5. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations. Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334 [TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related]
8. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421 [TBL] [Abstract][Full Text] [Related]
9. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876 [TBL] [Abstract][Full Text] [Related]
11. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048 [TBL] [Abstract][Full Text] [Related]
12. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Gazdar AF Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293 [TBL] [Abstract][Full Text] [Related]
13. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis. Nie W; Tao X; Wei H; Chen WS; Li B Oncotarget; 2015 Sep; 6(28):25696-700. PubMed ID: 26325082 [TBL] [Abstract][Full Text] [Related]
14. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Takeuchi S; Yano S Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378 [TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Sohn HS; Kwon JW; Shin S; Kim HS; Kim H J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647 [TBL] [Abstract][Full Text] [Related]
18. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561 [TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337 [TBL] [Abstract][Full Text] [Related]